Heron Therapeutics Q1 2024 GAAP EPS $(0.02) Beats $(0.09) Estimate, Sales $34.700M Beat $32.975M Estimate
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics (NASDAQ:HRTX) reported Q1 2024 earnings with a GAAP EPS of $(0.02), surpassing the $(0.09) estimate, and sales of $34.700M, exceeding the $32.975M estimate. This represents a 17.17% increase in sales compared to the same period last year.
May 07, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Heron Therapeutics reported better than expected Q1 2024 earnings and sales, indicating strong financial performance.
Beating both EPS and sales estimates significantly, especially with a 17.17% year-over-year sales increase, suggests operational efficiency and market demand for Heron's products. This positive earnings report is likely to instill investor confidence and could lead to a short-term uptick in HRTX's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100